DNA repair inhibitors to overcome drug resistance

Refining the role of PARP inhibitors in targeted anticancer therapy

Developments in immunotherapy

Putting adoptive T cell therapy on the path to regulatory approval

Mutant-specific kinase inhibitors and TAT highlights

New drugs and targets in haematological malignancies

Drugging the cancer genome to overcome drug resistance

ecancermedicalscience editor's choice for February 2015

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma

Impact of statins on survival outcomes in metastatic renal cell carcinoma